| 2.34 0.06 (2.63%) | 11-29 13:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.8 | 1-year : | 3.27 |
| Resists | First : | 2.4 | Second : | 2.8 |
| Pivot price | 2.21 |
|||
| Supports | First : | 2.1 | Second : | 1.91 |
| MAs | MA(5) : | 2.28 |
MA(20) : | 2.16 |
| MA(100) : | 1.83 |
MA(250) : | 1.97  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 78.5 |
D(3) : | 73.5 |
| RSI | RSI(14): 66.2 |
|||
| 52-week | High : | 5.53 | Low : | 1.21 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AADI ] has closed below upper band by 6.3%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.38 - 2.4 | 2.4 - 2.41 |
| Low: | 2.25 - 2.26 | 2.26 - 2.27 |
| Close: | 2.26 - 2.28 | 2.28 - 2.3 |
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Tue, 12 Nov 2024
BML Capital Management LLC Takes $4.12 Million Position in Aadi Bioscience, Inc. (NASDAQ:AADI) - MarketBeat
Wed, 06 Nov 2024
Aadi Bioscience Q3 Sales Surge 21% YoY, FYARRO Growth Drives Strong Performance | AADI Stock News - StockTitan
Wed, 06 Nov 2024
Aadi Bioscience Reports Q3 2024 Earnings and Growth - TipRanks
Wed, 06 Nov 2024
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update - PR Newswire
Fri, 27 Sep 2024
Wilson Sonsini Defeats $341 Million Arbitration Claim Against Aadi Bioscience - Wilson Sonsini
Wed, 21 Aug 2024
Aadi axes 80% of staff after registrational Phase II trial fails - Clinical Trials Arena
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 49 (%) |
| Shares Short | 281 (K) |
| Shares Short P.Month | 352 (K) |
| EPS | -2.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.79 |
| Profit Margin | -246.1 % |
| Operating Margin | -149.4 % |
| Return on Assets (ttm) | -35.3 % |
| Return on Equity (ttm) | -66 % |
| Qtrly Rev. Growth | 21 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.01 |
| EBITDA (p.s.) | -2.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -1.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.83 |
| Price to Sales | 2.3 |
| Price to Cash Flow | -1.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|